Suppr超能文献

大型多中心临床试验的最佳随机设计:来自美国国立卫生研究院卒中试验网络,由美国国立卫生研究院/国立神经病学与卒中研究所资助的经验。

Optimal Randomization Designs for Large Multicenter Clinical Trials: From the National Institutes of Health Stroke Trials Network Funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke Experience.

机构信息

Department of Public Health Sciences, Medical University of South Carolina, Charleston (W.Z., S.D.Y., V.L.D.-M., C.N.M., R.H.M., C.R.D., C.N.C., K.H.P., J.J.E.).

Departments of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute, University of Cincinnati Academic Health Center, OH (J.P.B.).

出版信息

Stroke. 2023 Jul;54(7):1909-1919. doi: 10.1161/STROKEAHA.122.040743. Epub 2023 Apr 20.

Abstract

From 2016 to 2021, the National Institutes of Health Stroke Trials Network funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke initiated ten multicenter randomized controlled clinical trials. Optimal subject randomization designs are demanded with 4 critical properties: (1) protection of treatment assignment randomness, (2) achievement of the desired treatment allocation ratio, (3) balancing of baseline covariates, and (4) ease of implementation. For acute stroke trials, it is necessary to minimize the time between eligibility assessment and treatment initiation. This article reviews the randomization designs for 3 trials currently enrolling in Stroke Trials Network funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke, the SATURN (Statins in Intracerebral Hemorrhage Trial), the MOST (Multiarm Optimization of Stroke Thrombolysis Trial), and the FASTEST (Recombinant Factor VIIa for Hemorrhagic Stroke Trial). Randomization methods utilized in these trials include minimal sufficient balance, block urn design, big stick design, and step-forward randomization. Their advantages and limitations are reviewed and compared with traditional stratified permuted block design and minimization.

摘要

从 2016 年到 2021 年,由美国国立卫生研究院/美国国立神经病学与卒中研究所资助的国家神经病学与卒中学会卒中试验网络发起了十项多中心随机对照临床试验。具有 4 个关键特性的最佳受试者随机化设计受到需求:(1)保护治疗分配的随机性,(2)实现所需的治疗分配比例,(3)平衡基线协变量,以及(4)易于实施。对于急性卒中试验,有必要将从资格评估到开始治疗的时间最小化。本文回顾了目前正在国家神经病学与卒中学会卒中试验网络资助下招募的 3 项试验的随机化设计,包括 SATURN(颅内出血试验中的他汀类药物)、MOST(卒中溶栓多臂优化试验)和 FASTEST(重组因子 VIIa 治疗出血性卒中试验)。这些试验中使用的随机化方法包括最小充分平衡、块 urn 设计、大棒设计和逐步随机化。本文还回顾并比较了它们的优点和局限性,以及与传统的分层随机区组设计和最小化设计的比较。

相似文献

2
Adaptive Randomization Method to Prevent Extreme Instances of Group Size and Covariate Imbalance in Stroke Trials.
Stroke. 2024 Aug;55(8):1962-1972. doi: 10.1161/STROKEAHA.123.046269. Epub 2024 Jun 26.
3
Minimal sufficient balance-a new strategy to balance baseline covariates and preserve randomness of treatment allocation.
Stat Methods Med Res. 2015 Dec;24(6):989-1002. doi: 10.1177/0962280212436447. Epub 2012 Jan 26.
4
A better alternative to stratified permuted block design for subject randomization in clinical trials.
Stat Med. 2014 Dec 30;33(30):5239-48. doi: 10.1002/sim.6266. Epub 2014 Jul 14.
5
Step-forward randomization in multicenter emergency treatment clinical trials.
Acad Emerg Med. 2010 Jun;17(6):659-65. doi: 10.1111/j.1553-2712.2010.00746.x.
6
Randomization in substance abuse clinical trials.
Subst Abuse Treat Prev Policy. 2006 Feb 6;1:6. doi: 10.1186/1747-597X-1-6.
10
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17.

引用本文的文献

1
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.
N Engl J Med. 2024 Sep 5;391(9):810-820. doi: 10.1056/NEJMoa2314779.
2
Evolution and Future of Stroke Trials.
Stroke. 2024 Jul;55(7):1932-1939. doi: 10.1161/STROKEAHA.123.044265. Epub 2024 Feb 8.

本文引用的文献

1
A roadmap to using randomization in clinical trials.
BMC Med Res Methodol. 2021 Aug 16;21(1):168. doi: 10.1186/s12874-021-01303-z.
2
The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods.
Int J Stroke. 2021 Oct;16(7):873-880. doi: 10.1177/1747493020978345. Epub 2020 Dec 9.
3
National Institutes of Health StrokeNet During the Time of COVID-19 and Beyond.
Stroke. 2020 Aug;51(8):2580-2586. doi: 10.1161/STROKEAHA.120.030417. Epub 2020 Jun 24.
4
Imbalance control in clinical trial subject randomization-from philosophy to strategy.
J Clin Epidemiol. 2018 Sep;101:116-118. doi: 10.1016/j.jclinepi.2018.02.022. Epub 2018 Mar 5.
5
Guessing strategies for treatment prediction under restricted randomization with unequal allocation.
Contemp Clin Trials. 2017 Aug;59:118-120. doi: 10.1016/j.cct.2017.05.009. Epub 2017 May 16.
6
The asymptotic maximal procedure for subject randomization in clinical trials.
Stat Methods Med Res. 2018 Jul;27(7):2142-2153. doi: 10.1177/0962280216677107. Epub 2016 Nov 16.
7
StrokeNet Takes Off: National Institute of Neurological Disorders and Stroke Organizational Update.
Stroke. 2016 Mar;47(3):e51-2. doi: 10.1161/STROKEAHA.115.012063. Epub 2016 Jan 26.
8
The National Institutes of Health StrokeNet: A User's Guide.
Stroke. 2016 Feb;47(2):301-3. doi: 10.1161/STROKEAHA.115.011743. Epub 2015 Dec 29.
9
A better alternative to stratified permuted block design for subject randomization in clinical trials.
Stat Med. 2014 Dec 30;33(30):5239-48. doi: 10.1002/sim.6266. Epub 2014 Jul 14.
10
Covariate imbalance and adjustment for logistic regression analysis of clinical trial data.
J Biopharm Stat. 2013;23(6):1383-402. doi: 10.1080/10543406.2013.834912.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验